/

AYTU

Aytu BioPharma, Inc.Closed

1.99+0.02 +1.02%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

2.01

Prev close

1.97

Day range

1.952.03

52-week range

1.803.07

Volume

24.51K0.71×

Mkt cap

21.62M

P/E ttm

—

Fwd P/E

12.84

EPS ttm

-1.16

Div yield

0.00%

Earnings

—

From 52w high

−35.18%

Price Chart

Yahoo Finance · delayed

AYTUOct 13, 2026O 1.96H 2.03L 1.95C 1.99+0.02 (+1.02%)Vol 24.50K

SMA 502.20
SMA 2002.36

1Y change −14.96% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AYTU Aytu BioPharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.93%
1 month: 0.00%
3 months: −9.55%
6 months: −22.27%
Year to date: −23.46%
1 year: −14.96%

Valuation & ownership

Market cap: 21.62M
Enterprise value: 13.42M
P/E (ttm): —
Forward P/E: 12.84
PEG ratio: —
Price / book: 0.61
Price / sales (ttm): 0.38
EV / EBITDA: -3.06
EPS (ttm): -1.16
EPS (forward): 0.1550
Beta (5y monthly): 0.18
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 10.87M
Float: 7.69M
Short % of float: 3.69%
Short ratio (days): 7.10
Held by insiders: 8.16%
Held by institutions: 35.51%
Avg volume (3m): 34.54K
50-day average: 2.21
200-day average: 2.37
52-week change: −14.96%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 37.1
vs 50-day SMA: −9.57%
vs 200-day SMA: −15.79%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.68%
Realised vol (20d, ann.): 40.0%
From 52-week high: −35.18%
From 52-week low: +10.56%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

9.67

+385.76% implied

Low 7.00Median 7.00High 15.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0

DES

About Aytu BioPharma, Inc.

Yahoo Finance profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 75
Headquarters: Denver, CO, United States
Website: aytubio.com
Officers: Mr. Joshua R. Disbrow CEO & Director
Mr. Ryan J. Selhorn CPA CFO, Corporate Secretary & Treasurer
Mr. Jarrett T. Disbrow Ph.D. Chief Business Officer

SEAS

Seasonality · AYTU

2008–2026 · monthly returns

Strongest month Aug +49.66%Weakest month May −14.22%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.0	-1.2	6.2	-5.5	-11.2	-6.1	3.7	2.7	-6.6	-7.0			−23.5%
2025	-1.8	-22.8	-7.0	12.5	31.9	22.5	11.9	-3.7	-20.0	20.7	-3.5	18.7	+52.9%
2024	-3.9	5.9	5.2	-7.6	12.1	-7.3	-9.2	-5.7	-6.0	-18.3	-16.1	5.6	−40.1%
2023	-13.2	-19.4	-15.8	4.9	-28.9	-4.2	13.1	-6.1	58.8	1.1	-16.1	24.0	−25.3%
2022	-3.0	-3.8	-14.3	-40.7	-14.1	25.5	-24.6	-57.7	-13.6	-15.8	31.2	-9.5	−85.9%
2021	19.4	7.4	-0.9	-12.9	-23.3	-1.4	-20.8	-4.3	-24.2	-13.5	-21.3	-31.1	−77.4%
2020	-25.8	-26.4	183.0	9.3	-9.1	-4.7	-2.1	-23.7	12.3	-20.2	-7.4	-32.0	−38.4%
2019	49.4	-0.8	42.7	22.8	-21.5	17.4	-17.5	-10.9	-12.9	-14.9	-18.4	15.5	+22.8%
2018	30.5	-78.0	0.0	-26.6	-27.7	-23.5	30.8	-36.6	-36.0	-61.6	-4.7	-21.8	−98.2%
2017	-14.2	-8.7	-4.3	-16.7	-13.3	-9.2	-1.7	-67.7	6.7	-17.5	-13.9	-21.5	−90.7%
2016	-74.7	-33.7	1.6	-34.4	-4.8	-2.5	-16.7	-3.8	-13.1	-57.1	-15.0	0.8	−97.3%
2015	31.6	0.0	-20.0	100.0	2.5	-92.4	0.0	1150.0	0.0	-5.3	-26.7	13.6	+61.8%
2014	0.0	0.0	42.9	2.0	-43.1	-31.0	0.0	-15.0	11.8	0.0	0.0	0.0	−45.7%
2013	0.0	0.0	-14.3	-41.7	-14.3	-16.7	-20.0	0.0	0.0	75.0	0.0	0.0	−50.0%
2012	0.0	120.0	-74.0	250.0	-71.4	250.0	0.0	0.0	0.0	0.0	0.0	0.0	+100.0%
2011	56.2	0.0	104.0	-41.2	-16.7	0.0	12.0	0.0	0.0	25.0	0.0	0.0	+118.7%
2010	-2.0	0.0	-22.4	0.0	0.0	-73.7	70.0	0.0	0.0	17.6	0.0	-20.0	−68.0%
2009	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-70.6	233.3	0.0	-68.0	212.5	−2.0%
2008										215.6	-49.5	0.0	+59.4%

INSD

Insider Activity · AYTU

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 27, 2026	Liu Vivian HDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jul 27, 2026	Disbrow Joshua R.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	30K	—
Jul 27, 2026	Dockery Carl CDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jul 27, 2026	Disbrow Jarrett TOfficer	Stock Award(Grant) at price 0.00 per share.	15K	—
Jul 27, 2026	Selhorn Ryan JChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	25K	—
Jul 27, 2026	Pyszczymuka GregOfficer	Stock Award(Grant) at price 0.00 per share.	20K	—
Jul 27, 2026	Jain AbhinavDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Oct 2, 2025	Liu Vivian HDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Oct 2, 2025	Disbrow Joshua R.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	53.9K	—
Oct 2, 2025	Dockery Carl CDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Oct 2, 2025	Disbrow Jarrett TOfficer	Stock Award(Grant) at price 0.00 per share.	32.1K	—
Oct 2, 2025	Selhorn Ryan JChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	33.7K	—
Oct 2, 2025	Pyszczymuka GregOfficer	Stock Award(Grant) at price 0.00 per share.	12.5K	—
Oct 2, 2025	Jain AbhinavDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 8, 2025	Disbrow Joshua R.Chief Executive Officer	Purchase at price 2.11 per share.	66.7K	$140.66K
Jun 8, 2025	Disbrow Jarrett TOfficer	Purchase at price 2.11 per share.	16.7K	$35.16K
Mar 30, 2025	Pyszczymuka GregOfficer	—	209	—
Feb 27, 2025	Disbrow Joshua R.Chief Executive Officer	Purchase at price 1.30 per share.	15K	$19.50K
Feb 4, 2025	Selhorn Ryan JChief Financial Officer	—	105	—
Dec 30, 2024	Pyszczymuka GregOfficer	—	208	—

13F

Investors Holding AYTU

latest 13F filings of 29 followed managers

Investors holding AYTU
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$225.4K	0.00%	104.82K	+12%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

AYTU

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AYTU

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Aytu BioPharma, Inc.

Seasonality · AYTU

Insider Activity · AYTU

Congress Trades · AYTU

Investors Holding AYTU

Investors Holding AYTU

Congress Trades · AYTU

Insider Activity · AYTU

Seasonality · AYTU

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Aytu BioPharma, Inc.

Financial Snapshot

Earnings & Dividends

News